June 2-5, 2018 | Washington, D.C.
Preclinical data shows equivalence of TP-252 and EPA-FFA in modulating inflammatory eicosanoid profiles within the colon EPA-FFA has demonstrated clinical efficacy in reducing the rate of relapse in ulcerative colitis BRANFORD, CT May 8, 2017 – Thetis Pharmaceuticals, a biopharmaceutical company developing novel small molecule drugs for inflammatory bowel disease (IBD), today announced pre-clinical data […]
– Lead candidate TP-252 expected to begin clinical studies in 2018 BRANFORD, CT– (May 5, 2017) – Thetis Pharmaceuticals LLC (“Thetis”), a biopharmaceutical company developing small molecule drugs for treatment of gastrointestinal diseases, announced two development candidates, TP-252 and TP-317, for treatment of inflammatory bowel disease (IBD). Gary Mathias, co-founder and chief executive officer, commented, […]
Inflammation is the protective biological response to infection, irritation, and injury. The inflammatory response is vital to survival, but can cause inadvertent damage if not carefully controlled. This is particularly true in the gastrointestinal (GI) tract, which is home to trillions of microbes and constantly exposed to inflammatory stimuli. As a result, the inner lining […]